TC
JAZZ icon

TFS Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

TFS Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,684
Closed -$213K – 1466
2013
Q4 		$213K Buy
+1,684
New +$174K 0.01% 1264

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TFS Capital's JAZZ Position: Q1 2014 in Review

TFS Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2014, closing a stake of 1,684 shares — an estimated $213K sold.

TFS Capital first reported a position in JAZZ in Q4 2013 and held it in 1 quarter. The position peaked at $213K in Q4 2013. 318 funds tracked by Wall St. Rank hold JAZZ as of Q1 2014.

  • TFS Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • TFS Capital sold 1,684 Jazz Pharmaceuticals shares in Q1 2014, an estimated $213K.
  • TFS Capital first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • TFS Capital's Jazz Pharmaceuticals position peaked at $213K in Q4 2013.
  • 318 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2014.

Based on TFS Capital's 13F filing for Q1 2014, filed 5 May 2014.